1-Hydroxybenzotriazole → 7-{3-[3-(tert-Butyldimethylsilanyloxy)propyl]isoxazol-5-yl}-6-[cyclopropyl-(2,3-dichlorobenzyl)carbamoyl]-3,9-diazabicyclo[3.3.1]non-6-ene-3,9-dicarboxylic acid 3-tert-butyl ester 9-(2,2,2-trichloro-1,1-dimethylethyl) ester

HRID 1096850ノート

反応式

HRID 1096850 の反応式
[Cl:1][C:2]([Cl:45])([Cl:44])[C:3]([O:6][C:7]([N:9]1[CH:14]2[C:15]([C:34](O)=[O:35])=[C:16]([C:18]3[O:22][N:21]=[C:20]([CH2:23][CH2:24][CH2:25][O:26][Si:27]([C:30]([CH3:33])([CH3:32])[CH3:31])([CH3:29])[CH3:28])[CH:19]=3)[CH2:17][CH:10]1[CH2:11][N:12]([C:37]([O:39][C:40]([CH3:43])([CH3:42])[CH3:41])=[O:38])[CH2:13]2)=[O:8])([CH3:5])[CH3:4].[CH:46]1([NH:49][CH2:50][C:51]2[CH:56]=[CH:55][CH:54]=[C:53]([Cl:57])[C:52]=2[Cl:58])[CH2:48][CH2:47]1.CCN(C(C)C)C(C)C.C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.Cl>CN(C1C=CN=CC=1)C.C(Cl)Cl>[Cl:44][C:2]([Cl:1])([Cl:45])[C:3]([O:6][C:7]([N:9]1[CH:14]2[C:15]([C:34](=[O:35])[N:49]([CH:46]3[CH2:47][CH2:48]3)[CH2:50][C:51]3[CH:56]=[CH:55][CH:54]=[C:53]([Cl:57])[C:52]=3[Cl:58])=[C:16]([C:18]3[O:22][N:21]=[C:20]([CH2:23][CH2:24][CH2:25][O:26][Si:27]([C:30]([CH3:33])([CH3:32])[CH3:31])([CH3:29])[CH3:28])[CH:19]=3)[CH2:17][CH:10]1[CH2:11][N:12]([C:37]([O:39][C:40]([CH3:43])([CH3:42])[CH3:41])=[O:38])[CH2:13]2)=[O:8])([CH3:4])[CH3:5]

参加物

8

反応物 5

HCID 757711-HydroxybenzotriazoleHCID 81531DiisopropylethylamineHCID 834599Cyclopropyl-(2,3-dichloro-benzyl)-amineHCID 27239391,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochlorideHCID 866370667-{3-[3-(tert-Butyldimethylsilanyloxy)propyl]isoxazol-5-yl}-3,9-diazabicyclo[3.3.1]non-6-ene-3,6,9-tricarboxylic acid 3-tert-butyl ester 9-(2,2,2-trichloro-1,1-dimethylethyl) ester

生成物 1

HCID 866370697-{3-[3-(tert-Butyldimethylsilanyloxy)propyl]isoxazol-5-yl}-6-[cyclopropyl-(2,3-dichlorobenzyl)carbamoyl]-3,9-diazabicyclo[3.3.1]non-6-ene-3,9-dicarboxylic acid 3-tert-butyl ester 9-(2,2,2-trichloro-1,1-dimethylethyl) ester収率 35.2%

試薬・触媒・溶媒 2

HCID 142844-(Dimethylamino)pyridine触媒HCID 6344Dichloromethane溶媒2 回

実験手順

A mixture of compound D3 (355 mg, 0.500 mmol), cyclopropyl-(2,3-dichlorobenzyl)-amine (prepared from 2,3-dichlorobenzaldehyde and cyclopropylamine by reductive amination, 324 mg, 1.50 mmol), DIPEA (0.342 mL, 2.00 mmol), DMAP (15.3 mg, 0.125 mmol), HOBt (101 mg, 0.75 mmol) and EDC.HCl (288 mg, 1.50 mmol) in CH2Cl2 (7 mL) was stirred at rt for 2 weeks. The mixture was diluted with more CH2Cl2, and washed with aq. 1M HCl (3×) and aq. sat. NaHCO3 (1×). The org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC (EtOAc/heptane 1:9→2:8 3:7→4:6→1:1) yielded the title compound (160 mg, 35%). LC-MS: tR=1.34 min, ES+: 909.35.

後処理

  1. washwashed with aq. 1M HCl (3×) and aq. sat. NaHCO3 (1×)
  2. dry with materialextracts were dried over MgSO4
  3. filtrationfiltered
  4. customthe solvents were removed under reduced pressure
  5. customPurification of the residue by FC (EtOAc/heptane 1:9→2:8 3:7→4:6→1:1)

出典と根拠

ORDレコード
ord-e2e4601b702b421bad68d107514d8a5b
出典データセット
uspto-grants-2012_03
特許番号
US08138340B2

反応ノート

読み込み中…